CA2384502C - Use of .alpha.-linolenic acid metabolites for treatment or prevention of cancer - Google Patents

Use of .alpha.-linolenic acid metabolites for treatment or prevention of cancer Download PDF

Info

Publication number
CA2384502C
CA2384502C CA2384502A CA2384502A CA2384502C CA 2384502 C CA2384502 C CA 2384502C CA 2384502 A CA2384502 A CA 2384502A CA 2384502 A CA2384502 A CA 2384502A CA 2384502 C CA2384502 C CA 2384502C
Authority
CA
Canada
Prior art keywords
acid
cancer
metabolite
day
epa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2384502A
Other languages
English (en)
French (fr)
Other versions
CA2384502A1 (en
Inventor
Mark Obukowicz
Ayman Kabakibi
Susan Hummert
Lisa M. Olson
Julie Lindemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monsanto Technology LLC
Original Assignee
Monsanto Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Technology LLC filed Critical Monsanto Technology LLC
Publication of CA2384502A1 publication Critical patent/CA2384502A1/en
Application granted granted Critical
Publication of CA2384502C publication Critical patent/CA2384502C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2384502A 1999-09-10 2000-09-11 Use of .alpha.-linolenic acid metabolites for treatment or prevention of cancer Expired - Fee Related CA2384502C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/393,790 1999-09-10
US09/393,790 US6340705B1 (en) 1999-09-10 1999-09-10 Use of α-linolenic acid metabolites for treatment or prevention of cancer
PCT/US2000/024931 WO2001017517A2 (en) 1999-09-10 2000-09-11 Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer

Publications (2)

Publication Number Publication Date
CA2384502A1 CA2384502A1 (en) 2001-03-15
CA2384502C true CA2384502C (en) 2011-01-18

Family

ID=23556262

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2384502A Expired - Fee Related CA2384502C (en) 1999-09-10 2000-09-11 Use of .alpha.-linolenic acid metabolites for treatment or prevention of cancer

Country Status (9)

Country Link
US (2) US6340705B1 (https=)
EP (1) EP1237545B1 (https=)
JP (1) JP2003508484A (https=)
AT (1) ATE318133T1 (https=)
AU (1) AU7371600A (https=)
CA (1) CA2384502C (https=)
DE (1) DE60026152T2 (https=)
MX (1) MXPA02002681A (https=)
WO (1) WO2001017517A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037892A1 (en) * 2001-11-19 2004-02-26 Adrianne Bendich Dietary composition containing conjugated linoleic acid and calcium for improved health
WO2002092779A2 (en) * 2001-05-17 2002-11-21 Pilot Therapeutics, Inc. Method for enriching tissues in long chain polyunsaturated fatty acids
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
WO2005018632A1 (en) * 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
CN102127057A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
US7456270B2 (en) * 2004-09-01 2008-11-25 Abbott Laboratories Δ6-desaturase genes and uses thereof
DE202004015931U1 (de) * 2004-10-13 2005-01-05 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
US8092839B2 (en) * 2004-12-13 2012-01-10 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
US8431165B2 (en) * 2004-12-13 2013-04-30 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
US7481870B2 (en) * 2006-04-18 2009-01-27 Oreck Holdings, Llc Electrode wire for an electrostatic precipitator
EP2026828B1 (en) 2006-06-08 2015-04-15 The Procter and Gamble Company Use of at least one polyphenol for promoting eye health
FR2904554B1 (fr) * 2006-08-04 2010-11-05 Zheng Xu Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients porteurs de cancers multiples
US20100010088A1 (en) * 2007-11-01 2010-01-14 Wake Forest University School Of Medicine Compositions and Methods for Prevention and Treatment of Mammalian Diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
NZ586249A (en) * 2007-12-19 2012-05-25 Prometic Biosciences Inc A combination of medium-chain length fatty acids, salts or triglycerides, gemcitabine, and optionally erlotinib, for the treatment of pancreatic cancer
US20090197955A1 (en) * 2008-01-31 2009-08-06 Monsanto Company Methods of improving dha deposition and related function and/or development
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
US8372465B2 (en) 2010-02-17 2013-02-12 Bunge Oils, Inc. Oil compositions of stearidonic acid
EP2425833A1 (de) * 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
WO2012141575A1 (en) * 2011-04-14 2012-10-18 N.V.Nutricia Combination of epa, dpa and/or dha with a chemotherapeutic agent
US10076550B2 (en) * 2014-06-25 2018-09-18 Council Of Scientific & Industrial Research Synergistic pharmaceutical composition for gastroinestinal disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
HU203660B (en) * 1987-04-23 1991-09-30 Biogal Gyogyszergyar Improved process for producing food-additive composition rich in omega-3-unsaturated fatty acids
CN1035925C (zh) * 1988-11-16 1997-09-24 许正 亲细胞非均质分子脂质的制备方法
ES2059880T3 (es) * 1990-05-23 1994-11-16 Nestle Sa Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias.
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
EP0585058A1 (en) * 1992-08-25 1994-03-02 Scotia Holdings Plc Pharmaceutical compositions containing fatty acids and heparin
EP0585057A1 (en) * 1992-08-25 1994-03-02 Scotia Holdings Plc Lithium salts of fatty acids for the treatment of viral infections and cancer
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
KR970002037B1 (ko) * 1994-12-09 1997-02-21 농촌진흥청 들깨유로부터 α-리놀렌산(ALA)을 분리, 정제하는 방법
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
DE69622722T2 (de) 1996-11-20 2003-02-27 N.V. Nutricia, Zoetermeer Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung

Also Published As

Publication number Publication date
WO2001017517A2 (en) 2001-03-15
EP1237545B1 (en) 2006-02-22
US20020010211A1 (en) 2002-01-24
DE60026152T2 (de) 2006-11-16
AU7371600A (en) 2001-04-10
MXPA02002681A (es) 2003-10-14
ATE318133T1 (de) 2006-03-15
WO2001017517A3 (en) 2002-07-11
EP1237545A2 (en) 2002-09-11
US6340705B1 (en) 2002-01-22
JP2003508484A (ja) 2003-03-04
CA2384502A1 (en) 2001-03-15
DE60026152D1 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
CA2384502C (en) Use of .alpha.-linolenic acid metabolites for treatment or prevention of cancer
US9044446B2 (en) Metabolic imprinting effects of structured lipids
DE69935995T3 (de) Polyungesättigen fettsäuren nährungsergänzung
CN103458893B (zh) Sn‑1(3)单酰基甘油酯和脂质吸收
AU2005264781B2 (en) Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities
CZ20024173A3 (cs) Terapeutické kombinace mastných kyselin
US20180133190A1 (en) Monoacylglycerols and fat-soluble nutrients for use in the treatment of nutrient deficiency from maldigestion
US9687462B2 (en) Sn-2-monoacylglycerols and lipid malabsorption
Vázquez et al. Bioactive lipids
US20090203780A1 (en) Use of a Polyunsaturated Fatty Acid Compound
US20160263073A1 (en) Monoacylglycerols for use in the treatment of malabsorption having a mechanical basis
CA2906491C (en) Medicament for treatment of cancer, cardiovascular diseases and inflammation
Dachev et al. The Effects of Conjugated Linoleic Acids on Cancer. Processes 2021, 9, 454
Calder Polyunsaturated Fatty Acids
AYNA NUTRITIONAL AND HEALTH VALUE OF ESSENTIAL FATTY ACIDS
Acid Linolenic Acid (flax, walnut, soy, pumpkin, algea)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160912